FDA

biotech

Sarepta Takes Its Foot off the Gas

Considering that a Greek exit might be on the way, the broad markets have sold off a fair amount, and across the markets companies are losing out. Sarepta Therapeutics Inc. ...
Read Full Story »
145922793

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. This covers a new class of drugs in the PCSK9 classification, and FDA panels are ...
Read Full Story »
health care

6 Key Cancer Winners From ASCO Presentations

The American Society of Clinical Oncology, or ASCO, is currently having its annual meeting, in which companies and cancer drug developers share results from their most recent drug trials. The ...
Read Full Story »
fda_logo

How Sarepta Short Interest Is Adding to Its Gains

Usually, when biotech companies meet with the U.S. Food and Drug Administration (FDA), their stock goes one of two ways. In the case of Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares ...
Read Full Story »
DNA

Why This Study May Have Saved Pain Therapeutics

Both biotech and pharmaceutical companies have a mission to make life better for everyone through the innovation and production of drugs that can save lives. Pain Therapeutics Inc. (NASDAQ: PTIE) ...
Read Full Story »
Money background. Close-up.

What Is Really Driving Array Higher

Array BioPharma Inc. (NASDAQ: ARRY) released is fiscal third-quarter earnings before the markets opened Monday. The company reported a net loss of $0.11 per share on $6.6 million in revenue for the ...
Read Full Story »
health care

Will Schizophrenia and Bipolar Patients Trust Generic Abilify?

The trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics ...
Read Full Story »
145922793

A Real Heartbreak for Celladon

On its website, Celladon Corp. (NASDAQ: CLDN) writes “Hope to Heart Patients.” Not to sound morbid, but the company appears to have lost at least some hope – in terms of dollars ...
Read Full Story »
upgrade

GW Pharma Gets Big Analyst Upgrade Into Cannabinoid FDA Orphan Drug Designation

GW Pharmaceuticals PLC (NASDAQ: GWPH) was recently listed as the top medical marijuana stock for National Weed Day, but other things are going on here besides weird holidays. GW recently ...
Read Full Story »
chicks

How Much Do Companies Really Have to Worry About Bird Flu?

The world has never been able to get past the fears of viruses, outbreaks and contagion. Now bird flu is making its way back into the news, and the fears of ...
Read Full Story »
research

BioCryst Upgrade Almost Looks Misunderstood

The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) may be very misunderstood for what it is. The brokerage firm upgraded BioCryst to Neutral and ...
Read Full Story »
knees

Is Ampio at Risk of Imploding?

Companies in the biotech and pharmaceuticals field are generally riskier than other companies because a single failed study could make or break the company, similar to what happened with Ampio ...
Read Full Story »
cannabis

Is Legalized Marijuana Coming to 3 More States?

The efforts and controversy behind medical marijuana and legalized marijuana for recreational use have been at a crossroads for some time. Several states have legalized marijuana for recreational and medical ...
Read Full Story »
thumbs up

Analysts Massively Increasing Dyax Price Targets

The next hot biotech stock could very well be Dyax Corp. (NASDAQ: DYAX). With biotech such a hot sector of late, investors are likely to pay close attention to this ...
Read Full Story »
health care

Why Dyax Will Dominate Biotech News on Wednesday

Dyax Corp. (NASDAQ: DYAX) is almost certain to dominate the biotech news flow on Wednesday. The company announced positive data on Tuesday evening from the Phase 1b clinical study of the ...
Read Full Story »